Potential coronavirus vaccine shows early promise

Massachusetts biotechnology company Moderna announced Monday that its potential COVID-19 vaccine showed promising early clinical trial results. Eight patients developed antibodies at levels similar to those of people who recovered from the coronavirus.

Moderna described the interim data as “positive,” with Chief Medical Officer Tal Zaks saying that the findings, though preliminary, “substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”

Moderna’s stock soared on the news, lifting much of Wall Street with it.

The Dow Jones Industrial Average gained 912 points or nearly 3.9 percent, while the S&P 500 closed up by nearly 3.2 percent.

Moderna is developing the vaccine with the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center.

%d bloggers like this: